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Objectives: Upon completion of this article, the reader will be
able to identify the basis for treating bone and soft tissue
tumors with various thermal and chemical ablationmethods.
In addition, the reader should be able to explain the expected
outcomes and how to minimize procedure-related
complications.
Accreditation: This activity has been planned and imple-
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the Accreditation Council for Continuing Medical Education
(ACCME) through the joint providership of Tufts University
School of Medicine (TUSM) and Thieme Medical Publishers,
New York. TUSM is accredited by the ACCME to provide
continuing medical education for physicians.
Credit: Tufts University School of Medicine designates this
journal-based CME activity for a maximum of 1 AMA PRA
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activity.
Bone and soft tissue tumors present unique treatment
challenges with a multitude of treatment options including
external beam radiation, surgery, minimally invasive abla-
tions, hormonal therapy, and chemotherapy. The technologi-
cal advances achieved over the past few decades have allowed
significant evolution of ablation procedures guided by mod-
ern imaging methods. Early ablations were conducted on
abdominal visceral organs, and subsequently much has been
learned about its clinical uses and complications. This knowl-
edge served as the forerunner to skeletal and soft tissue
ablation. Initial reports utilizing thermal ablation used to
treat tumors of themusculoskeletal system date back to 1992
with the description by Rosenthal et al ablating osteoid
osteomas (OOs).1 Since then, there has been widespread
use of thermal and chemical ablation in the treatment of
musculoskeletal tumors. Not only has radiofrequency abla-
tion (RFA) replaced surgical resection for osteoid osteoma
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Abstract Bone and soft tissue tumor ablation has reached widespread acceptance in the
locoregional treatment of various benign and malignant musculoskeletal (MSK) lesions.
Many principles of ablation learned elsewhere in the body are easily adapted to the MSK
system, particularly the various technical aspects of probe/antenna design, tumoricidal
effects, selection of image guidance, andmethods to reduce complications. Despite the
common use of thermal and chemical ablation procedures in bone and soft tissues,
there are few large clinical series that show longitudinal benefit and cost-effectiveness
compared with conventional methods, namely, surgery, external beam radiation, and
chemotherapy. Percutaneous radiofrequency ablation of osteoid osteomas has been
evaluated the most and is considered a first-line treatment choice for many lesions.
Palliation of painfulmetastatic bone disease with thermal ablation is considered safe and
has been shown to reduce pain and analgesic use while improving quality of life for
cancer patients. Procedure-related complications are rare and are typically easily
managed. Similar to all interventional procedures, bone and soft tissue lesions require
an integrated approach to disease management to determine the optimum type of and
timing for ablation techniques within the context of the patient care plan.
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decreased morbidity2 but new techniques including cryoa-
blation, cementoplasty,microwave, laser, focused ultrasound,
and electroporation have also been developed. Given the
success of these minimally invasive therapies, many orthope-
dic surgeons, oncologic physicians, and interventional radi-
ologists worldwide consider ablation techniques for a variety
of bone and soft tissue tumors for cure and palliation. This
article of Seminars in Interventional Radiology explores the
most recent clinical indications and outcomes for bone and
soft tissue ablation, as well as an update to the previous
review by Kurup and Callstrom.3
Primary Bone Tumor Ablations
Osteoid Osteomas
These small benign bone tumors were originally described by
Jaffe in 1935.4 OOs are a relatively common bone lesion
accounting for approximately 10% of all benign bone tumors.5
They tend to occur in children and young adults with a male
preponderance. Classically, these lesions are associated with
intermittent pain that is worse at night and relieved with
nonsteroidal anti-inflammatory drugs. OOs are most often
cortically based, diaphyseal or metaphyseal, and most fre-
quently found in the femur or tibia. They are composed of an
osteoid nidus with a peripheral ring of highly vascularized
fibrous connective tissue.5 They can be associated with
scoliosis, bowing deformities, and cartilage injury depending
on their location. As a result, either for pain relief or to prevent
long-term sequelae, patients seek expedient definitive
therapy.
Curative treatment of these tumors, which are often less
than 1 cm in size, is achieved by nidus elimination. OOs are
highly innervated and very painful during ablation and
therefore usually require general anesthesia. Lesion access
is obtained by drill or large-bore needle using computed
tomography (CT) fluoroscopy; a single tined RFA probewith a
5 to 10 mm tip is inserted so that the tip lies within the
epicenter of the osteoma (►Fig. 1). The electrode is then
heated to 90°C for 4 to 6 minutes and allowed to cool. After
complete tumor coverage, the electrode is removed.
Clinical studies have reported high rates of success in
patients with OOs treated with RFA. Rosenthal et al reported
on 263 patients with OOs treated with RFA for which 2-year
follow-up data were available for 126 patients.6 Of these, 117
(89%) reported complete symptom relief. Rimondi et al
reported on 557 nonspinal OOs treated with RFA and re-
ported a primary success rate of 96% (533 cases) and a
secondary success rate of 99.6% (555 cases) following rea-
blation.7 Gebauer et al performed ablations on 59 OOs with
complete pain relief in 51 patients (89.2%) following a single
ablation and 56 patients (97.9%) following a second ablation.8
In the same study, a meta-analysis was performed that
included 1,356 patients and 20 clinical studies, reporting
an overall primary success rate of 92%.
There is no difference in the recurrence rate of surgically
resected OOs versus ablated OOs, and the complication rates
are lower with ablations.2 Rosenthal and others’ combined
study group of 125 patients yielded a recurrence rate of 9% in
the surgical group and 12% in the ablated group, the differ-
ence of which was not statistically significant.2 A systematic
review of the literature in 2013 by Lanza et al demonstrated
the average rate of recurrence following ablation among 27
articles and 1,772 patientswas 4.9%.9 Themeta-analysis of OO
ablations of Gebauer et al in 1,187 patients across 13 studies
reported a collective complication rate of 2.9% (ranging from
1 to 8%).8
Laser-induced thermotherapy (LITT) has also been used
successfully to eliminate OOs. LITT uses optical fibers that
deliver infrared light into tissue causing irreversible cellular
destruction from thermal injury. Most current systems con-
sist of a Nd:YAG laser with awavelength of 1,064 nm or diode
lasers with wavelengths of 980 or 805 nm. During ablation,
the applicators are actively cooled to prevent charring of the
target. A spherical ablation volume in bone of 2.0 cm in
Figure 1 A 44-year-old man with recent onset radiating hip to mid-
thigh pain. (A) Axial CT with cortical thickening and lucent lesion with
central sclerotic nidus consistent with osteoid osteoma (arrow).
Overlying skin grid used during lesion targeting for safe access
window. (B) Initial biopsy needle for tissue sample was inserted, and
the RFA probe tip was advanced into the central portion of the lesion.
CT, computed tomography; RFA, radiofrequency ablation.
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diameter can be achieved by light energy of 2.0 W when
delivered by closely grouped fibers.10 Larger volumes can be
ablated by spreading apart the optical fibers before insertion.
Ablation time varies in the literature from6 to 10minutes and
is determined by nidus size.
LITT is magnetic resonance imaging (MRI) and CT compat-
ible, a major advantage of the system. MRI guidance permits
additional accurate mapping during treatment while elimi-
nating radiation exposure in young OO patient populations.
Unfortunately, bone biopsy devices are noncompatible with
MRI laser sets; therefore, biopsies are not possible to perform
during the procedure. Fortunately, the diagnosis is often
obvious on imaging before the ablation, but if necessary CT
can be used to initially guide a biopsy followed by radio-
frequency or laser ablation. Other benefits of laser ablation
include a more predictable volume of energy deposition to
target tissues and introduction via an 18-gauge spinal needle,
reducing the needle size required for RFA.
Laser photocoagulation was first reported in 1997 by
Gangi et al with a cohort of 15 patients in which CT guidance
was used.11 Since that time, there have been numerous
reports demonstrating high technical and primary success
rates with few complications.12–15 The largest study pub-
lished by Gangi et al in 2007 (N ¼ 114) yielded a primary
success rate of 93% (106 patients), recurrence in 5% (6 cases),
and only one minor postprocedural complication of tempo-
rary reflex sympathetic dystrophy.13 The first successful laser
ablation of an OO with an open system 0.23T MRI was
reported in 2003 by Sequeiros et al, a technique that contin-
ued to evolve with high-field 1.0 TMRI to guide laser ablation
with continuous thermal monitoring (MR thermogra-
phy).16,17 A recent study in Germany byMaurer et al outlined
a cost comparison of CT-guided RFA versus MR-guided laser
ablation, and showed that MR-guided laser ablation was less
expensive by 20%.18 Their price extrapolations with identical
assumptions showed CT-guided LITT had the lowest cost,
being 44.5% less than CT-guided RFA and 31% less than MR-
guided laser.
Chondroblastoma
Another benign primary bone tumor considered for ablation
in the past 15 years is chondroblastoma (CB). Originally
described by Jaffe and Lichtenstein in 1942, these rare tumors
of children/young adults are located in the epiphyses/apoph-
yses, are often painful, and can limit range of motion.19 CBs
have typically been treated with operative curettage; howev-
er, complications such as limb shortening and premature
osteoarthritis were frequent given their proximity to the
growth plate and cartilage. The rarity of this tumor prevents
large-scale studies, but since 2001 case reports have been
published describing successful RFA for tumor elimina-
tion.20–25 RFA offers several advantages, similar to OOs,
including a shorter postoperative hospital stay (most studies
report a single day or overnight stay). Recurrence rates
following surgery range from 10 to 35%, whereas with RFA
treatment there have been no reported recurrences.26–29 This
suggests that RF ablation is a safe and effective alternative to
surgery for smaller CBs when proximity to cartilage and
growth plates and weight-bearing surface location are taken
into account.
CBs are often painful and ablation requires general anes-
thesia. Probe size is chosen based on tumor volume and may
require electrode repositioning and serial ablations to ensure
complete tumor coverage. Single-tined probes have been
postulated to have fewer complications than multi-tined
probes.21,24 Given the predictable and uniform ablation field
produced, bipolar probes may be a valuable asset in the
treatment of CBs in close proximity to cartilage or a physis.30
An important consideration relating to epiphyseal location is
to ensure the subchondral bone plate is excluded from the
ablation zone to avoid chondrolysis, osteonecrosis, and/or
articular surface collapse.24 Thus far, Rybak et al has reported
the largest number of CB ablations (N ¼ 17) with one adverse
outcome of delayed articular surface collapse (thought to be
secondary to residual viable tumor).21
Other Primary Bone Lesions
The use of ablation in the treatment of other benign bone
tumors has been expanded beyond OOs and CBs in the past
10 years. Corby et al reported on their experience in ablating
two solitary eosinophilic granulomas of bone.31 CT-fluoros-
copy–guided treatment and a multi-tined probe were used
due to larger lesion size, and no complications were experi-
enced. Critics raised concern for treating such large lesions
involving the weight-bearing axis because of pathologic
fracture risk.32 There have also been at least four case reports
of RFA and cryoablation of sacrococcygeal chordomas.33–36
Other slow growing but locally aggressive malignancies can
be difficult to completely resect and have high recurrence
rates and may be amendable to local ablation (►Fig. 2).
Metastatic Bone and Soft Tissue Ablations
Metastases are themost common bone lesions, with up to 85%
of patients who die from breast, prostate, or lung cancer
having pathologic evidence of osseous spread of disease.37
Complications related to bone metastases include pathologic
fracture, intractable pain, neurovascular impingement, and
decreased mobility, all of which can contribute to a dimin-
ished quality of life. Conventional therapies for pain manage-
ment include systemic treatments (e.g., chemotherapy,
hormones, radiopharmaceuticals, bisphosphonates, and an-
algesics) and local treatments (external beam radiation ther-
apy and surgery). Despite a vast array of available options,
pain related to bone and soft tissue metastatic deposits is
often inadequately treated and many times described as “the
worst” pain cancer patients experience.
External beam radiation therapy or surgery for oligometa-
static disease and systemic chemotherapy for widely dissem-
inated metastatic disease are the most often used initial
treatments for cure and palliation. External beam radiation
therapy remains the most accepted first-line therapy for
metastatic osseous disease, although lackof tumor sensitivity,
risk of damage to regional organs, or the inability to reirradi-
ate the same area may preclude its use. Radiation achieves
relief in approximately 60% of patients but is often
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temporary.38 Surgical fixation is reserved for patients with
recent or impending pathologic fractures, although many
patients are nonoperative candidates. With improved overall
patient survival among many cancer subsets, there has been
an increased interest in alternative locoregional therapies
including RFA, cryoablation, high-intensity focused ultra-
sound, laser ablation, and cementoplasty for pain manage-
ment and tumor reduction.
Soft tissue metastases can also be a source of severe pain,
ulceration, and mass effect. Many tumors are radiosensitive,
but their location renders external beam therapy harmful to
adjacent bowel or other viscera. In these instances, ablation
techniquesmay be employed. Certain soft tissue lesions of the
skin or other superficial locations may be amenable to
percutaneous ablation if skin temperature modulation is
possible to prevent ulceration (►Fig. 3).
Early reports indicate that percutaneous ablative treat-
ments may improve overall survival and life years gained, and
may be cost-effective.39 Discussion before ablative therapy
with the patient, family, and other caregivers is paramount to
establish treatment expectations, particularly if hospice care
is involved and non-resuscitation status is in place. A pre-
treatment pain assessment utilizing the Brief Pain Inventory
Short Form (BPI) orMemorial Pain Assessment Card (MPAC) is
necessary for quantitative posttreatment evaluation. A phys-
ical examwith imaging correlation is crucial to determine the
source(s) of pain and the safest approach for ablation.
Based on imaging findings, relative contraindications to
ablation include tumors that are less than 1 cm away from the
spinal cord, major motor nerves, and arteries supplying the
central nervous system, bladder, or bowel.40 Osteolytic and
mixed osteolytic/osteoblastic bone metastatic deposits are
most amenable to ablation. Purely, osteoblastic lesions can be
difficult to access due to their high density and are associated
with poor deposition of RFA energy.41
Most procedures are performed on an outpatient basis
with sedation or regional anesthesia. General anesthesia and
monitoring may be necessary for patients with elevated
baseline pain or on large doses of analgesics. With respect
to primary imaging guidance, CT is mainly used for osseous
and deeper soft tissue lesions, while ultrasound can be used
to guide superficial treatments. MRI has limited use due to
probe incompatibility.
The goal of probe/antenna placement is to destroy sensory
afferent nerves in the region of the lytic bone cortex, perios-
teum, and contiguous soft tissue tumor. Insertion of probes
within or adjacent to the area of bone destruction, rather than
in the bone itself, often provides the most effective treatment
and may reduce tumor stimulation factors and osteoclast
activity (►Fig. 3).
Figure 2 (A) A 60-year-old man with previous hemipelvectomy for large chondrosarcoma. Biopsy-proven recurrence near pseudoarticulation with
large mucoid component. (B) Prone CT post-cryoablation depicts ice zone (arrows) after probe removal. Four probes were placed due to the large
tumor size. (C) Two weeks later, the patient developed staphylococcal abscess at the treatment site requiring catheter drainage for an extended
period. Contrast sinogram via pigtail catheter (arrow) shows residual cavity. CT, computed tomography.
Figure 3 A 55-year-old man with local colorectal bone metastasis,
who failed external beam radiation therapy for pain control. He was
receiving 15 mg/hour hydromorphone basal rate patient-controlled
analgesia pump with breakthrough oral oxycodone. The patient was
lethargic with severe pain (10/10). Two microwave antennae were
placed adjacent to a destructive ilium soft tissue mass, and ablation
was performed at 65 W for 10 minutes. After treatment, the patient’s
pain and medication requirements lessened with an improved quality
of life during hospice.
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The two main types of ablative techniques are RFA and
cryoablation, which although both being thermal tools have
some differences. The use of thesemodalities for painful bone
and soft tissue metastasis has shown to be effective in
reducing pain and analgesic use (►Table 1). The American
College of Radiology Imaging Network study by Dupuy et al
using RFA showed continued pain improvement up to
3 months following ablation, and < 10% minor complication
rate.42 One of the primary goals of ablation is to incorporate
all interfaces between the tumor and adjacent normal bone in
the ablation field.43 Depending on the size of the tumor, a
single-tined electrode (ranging from 14 to 17 gauges) or a
multi-tined electrode may be selected. Multiple electrodes
with overlapping ablation fields may also be used for larger
lesions to ensure appropriate coverage. RFA is performed at
90 to 100°C for 5 to 10minutes. Following cooling of the probe
for 5minutes, it may be repositioned and subsequent ablation
performed if necessary. Bipolar devices theoretically have
greater predictability and precision and have recently been
used to treat osseous spinal metastatic disease in both animal
and human models with success and few complications.44,45
Cryoablation has been shown to be effective and safe in the
treatment of bone metastases.46 A distinct advantage of this
method versus RFA is the ability tomonitor the developing ice
ball by intermittent CT or MRI. This allows for increased
precision of tumor coverage and ensures proper exclusion
of critical structures from ablation. The probes are larger than
those used in RFA (ranging from 11 to 17 gauges), and
multiple probes can be used synergistically to increase the
size of the ice ball. Multiple probes must be placed approxi-
mately 1 cm from the tumor margins and 2 cm from each
other. The ablation involves a 10-minute freeze, 5-minute
thaw, and then a second 10-minute freeze, but there are
numerous reported variations on freeze–thaw–freeze cycles
that depend on tumor type and size. In relation to RFA, there
is less procedural pain and reports also suggest slightly longer
term pain relief.
Bone Augmentation: Cementoplasty
Cementoplasty, also called osteoplasty, involves the percuta-
neous injection of polymethylmethacrylate (PMMA) cement
into bone. PMMA stabilizes microfractures and is often used
in the treatment of osteoporotic or tumor-related spinal
compression fractures (i.e., vertebroplasty). Cementoplasty
can be used alone or in conjunction with RFA (►Fig. 4). Some
authors suggest there may be a synergistic effect when using
these techniques together, given the thermal effects of RFA
and the tumoricidal effects of PMMA.47 In the event that RFA
will be followed by cementoplasty, it is important to obtain
access with larger gauge needles to allow for the injection of
the cement. As well, the use of fluoroscopy or CT fluoroscopy
during cement injectionwill provide feedback to better direct
the cement instillation.
There are many successful reports in the literature using
this technique to treat pain referable to an underlying meta-
static deposit.47–49 Anselmetti et al treated extraspinal me-
tastases with cement alone in 43 patients and with
combination RFA and cementoplasty in 7 patients.48 His
group found a statistically significant reduction in mean
pain scale from 9.1 to 2.1, which was associated with a
decreased need for postprocedural analgesia medications.
Interestingly, there was no statistical difference (p ¼ 0.83)
between the two groups with respect to pain reduction,
although a study with larger sample sizes would be needed
to draw a firm conclusion regarding the possibility of synergy
with cementoplasty and RFA. Munk et al reported on 25 RFA
procedures followed by cementoplasties in 19 patients with
painful neoplastic lesions of bone; these authors reported a
100% technical success rate and significant reduction in
pain.47 Sevenminor complications occurred including limited













Callstrom et al84 2002 12 RFA 8/10 reduction 8/3.1 None
Goetz et al80 2004 43 RFA Decreased at




Callstrom, et al46 2006 14 Cryoablation 8/8 6.7/1.4 None
Thanos et al81 2008 30 RFA 27/30 6.8/4.7 (mean pain) None
Dupuy et al42 2010 55 RFA Not reported Reduction















Callstrom et al82 2013 61 Cryoablation Not reported 7.1/5.1 1—osteomyelitis
Abbreviation: RFA, radiofrequency ablation.
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cement extravasations and transient thermal nerve injury.
Lane et al performed 53 combined RFA and cementoplasty
procedures on painful bone metastasis with similar results of
considerable pain reduction and decreased patient need for
analgesia, with minimal complications.49
Soft Tissue Ablations
Desmoid tumors are the most frequently reported soft tissue
lesions treated by thermal ablation, and have formed the
foundation for other tissue tumor management protocols.
Desmoid tumors represent highly differentiated monoclonal
type fibroblasts with profuse collagen activity, which grow
along fascial planes, causing local infiltration and compres-
sion of adjacent structures. Theymay have superficial (fascial)
or deep (musculoaponeurotic) locations and varying degrees
of biologic behavior.50 The incidence of desmoids in the
general population is two to four cases per million per year,
which corresponds to approximately 900 new cases per year
in the United States.51,52 Those associated with Gardner
syndrome and familial adenomatous polyposis may have an
incidence up to 16%.51–53
Desmoids are commonly categorized into two types, those
of abdominal and extra-abdominal location. Multiple treat-
ment methods have been used, including surgical resection,
external radiation, and chemotherapy. These lesions are
aggressive, and recurrence is common; repeated surgeries
are necessary in certain populations for local tumor control.
Treatment strategies for symptomatic desmoids are ongoing,
with surgery as a first-line therapy and adjunctive radiation
treatment if necessary for positive margins.50,54 For recalci-
trant lesions where functional sparing surgery and radiation
are not options, thermal ablation has provided local control in
certain cases.55 The oftentimes superficial location, avascular/
hypovascular nature, and patient/physician frustration with
conventional therapies allow desmoids to serve as a good
model for percutaneous ablation therapies (►Fig. 5). If local
control fails with percutaneous ablation methods, nothing
has been lost, as other treatment options can still be pursued.
Other benign soft tissue tumors and lesion such as fibro-
mas, neurofibromas (with or without neurofibromatosis type
1 [NF-1] or 2), keloid scars, and vascular malformations may
show promise of symptom improvement with percutaneous
ablation techniques. NF-1 is reported to have an 8 to 13%
Figure 4 Multimodality treatment in 65-year-old nonambulatory man with metastatic renal cell cancer and severe right hip pain. (A) Coronal
reconstruction CT scan demonstrates an acetabular osteolytic lesion and intra-articular fracture (arrow). (B) Preembolization angiogram
demonstrating a hypervascular lesion (arrow) treated with particle embolization. (C) The patient suffered recurrent pain, and subsequent bone
RFA was performed along the superior aspect of the lesion. (D) Cementoplasty augmentation after RFA was performed in to stabilize the joint. (E)
Six-month posttreatment plain film; the patient’s pain resolved and he was able to walk. CT, computed tomography; RFA, radiofrequency ablation.
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increased lifetime risk of malignant degeneration within
peripheral nerve sheath tumors, and treatment with thermal
ablation offers a nonsurgical option.56,57 Neurofibromas as-
sociated with persistent pain, nerve deficits, altered texture,
or those that have enlarged on serial exams should have a low
threshold for biopsy and treatment (►Fig. 6). Surveillance
with contrast MRI and positron emission tomography/CT
allows for early management of suspicious lesions, especially
in the more common NF-1 type.
Keloids, always occurring at the site of prior skin injury, are
defined as fibroproliferative tumors within the dermis that
produce excess collagen. These tumors progress, sometimes
exuberantly, but have no malignant potential. Numerous
treatments have been attempted that include surgical exci-
sion and grafting, radiotherapy, laser and intralesional in-
jections, and cryosurgery, all attempting to minimize
additional skin surface injury. The recent use of intralesional
cryoablation is promising and may offer an additional option
for this challenging problem.
Cornelis et al recently reported on cryoablation treatment
of symptomatic venous malformations.58 Though a small
series with short follow-up, therewas symptomatic improve-
ment at 6 months. This may prove beneficial for certain
vascularmalformations recalcitrant to standard conservative,
operative, medication, or sclerotherapy treatments.
Chemical Ablation of Benign Bone Tumors
Wide excision curettage with methacrylate or bone allograft
packing provides effective healing for most symptomatic
benign bone lesions such as aneurysmal and unicameral
bone cysts (ABC and UBC).59 On occasion, there is tumor
regrowth that necessitates further surgery, for instance, with
ABCs located near a growth plate (where recurrence rates
may be as high as 71%).60 The use of adjunctive percutaneous
chemical sclerosant therapy during surgical treatment of
UBCs, ABCs, and other lesions has long been used by ortho-
pedic surgeons. Primary percutaneous scleroablation of ABCs
has been recently described by Shiels and Mayerson as a
Figure 5 A 24-year-old woman professional dancer with recurring
abdominal wall desmoid since the age of 12, now causing pain and
inability to perform. She underwent multiple surgeries and chemo-
therapy. (A) Pretreatment MRI with large right rectus desmoid (arrow)
with adjacent small bowel. (B) Cryoablation probes and ice ball
formation (open arrow) with hydrodissection interface medially to
protect bladder and bowel. Overlying gloves with warmed saline were
placed for thermal skin insulation (solid arrow). (C) Six-month post-
treatment scan demonstrating decreased tumor size and firmness,
which allowed the patient to resume her dancing career. MRI, mag-
netic resonance imaging.
Figure 6 A 45-year-old with neurofibromatosis type 1 and new painful
medial thigh neurofibroma (NF). (A) Coronal contrast-enhanced MRI
shows NF enhancement. (B) PET/CT reveals FDG avid uptake in the
lesion. (C) Biopsy results were benign, but the patient opted cryoa-
blation for symptomatic control. CT scan performed during the
procedure with ice ball formation at NF site. The patient’s pain resolved
posttreatment, and has now been symptom free for 3 years. CT,
computed tomography; FDG, fluorodeoxyglucose; PET, positron
emission tomography.
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minimally invasive option.61 In their series of 20 patients
younger than 19 years treated with a doxycycline and 25%
albumin regimen, 15 were nonsurgical primary treatments.
These investigators demonstrated a 5% recurrence rate over a
24-month period, with the number of treatments ranging
from 2 to 14 sessions.61
Special considerations for percutaneous chemical bone
tumor ablation include (1) adequate tumor tissue diagnosis
(either by open orthopedic or needle biopsy); (2) use of large
gauge or cutting needles for cortical penetration into the
lesion; (3) pediatric and adult general anesthesia; (4) precise
total compartment treatment avoiding overfilling and control
of venous outflow to reduce local and distant sclerosant
complications; (5) postprocedural management of immobili-
zation, pain, and other complications; and (6) follow-up to
assess healing response and realization for repeated
treatments.
Usually, the bone lesions are superficial with a thinned
cortex and 14- to 25-gauge needles are adequate for lesion
access (►Fig. 7). Foamed solutions offer improved ultrasound
visualization to ensure the entire lesion is bathed with
solution to limit the opportunity of recurrence. Lesions that
fail surgical and intralesional injections may have another
underlying pathology, such as a coexisting giant cell tumor.
Chemical Ablation of Soft Tissue Tumors
Percutaneous chemical ablation has also been used in the
treatment of certain symptomatic fibrous soft tissue tumors,
most commonly aggressive fibromatosis, desmoid tumors,
and neurofibromas. As noted previously, primary manage-
ment is surgical resection and chemotherapy, but high recur-
rence rates (up to 25–70%) make less invasive treatment
methods a key second-line therapy. Since desmoid tumor
treatment is extremely difficult, multidisciplinary manage-
ment is necessary to provide effective therapies that include
thermal ablation (previously described) and chemical
injection.
There are no large series in the literature that detail the
effectiveness and safety of intralesional soft tissue injections
for symptom relief or tumor dissolution. Numerous chemical
solutions have been described for intralesional injections
including 50% acetic acid, dehydrated ethanol, steroids, and
chemotherapy agents. Staged treatment is necessary because
of lesion firmness and the small quantity of sclerosant that
can be injected. Ultrasound-guided monitoring (►Fig. 8) is
the favored imaging modality, and small gauge, side hole
needles such as the Whitaker (Becton Dickinson, Franklin
Lakes, NJ) or Sprotte (B. Braun Medical, Bethlehem, PA) offer
better dispersion into the lesion.
Additional Ablation Techniques
Various other techniques have been used for ablation of MSK
tumors including microwave, focused ultrasound, laser, and
electroporation, for which only limited data exist.
Microwave ablation uses a 14.5-gauge antenna to deliver
electromagnetic microwaves resulting in heating of tissue.
This technique may be faster than RFA, as it can reach higher
temperatures due to less influence from tissue impedance
and vascular cooling effects. Early reports demonstrating
palliative treatment of pain in osseous metastatic disease
have been promising.62,63
Focused ultrasound is a noninvasive technique where
sound waves are directed into and concentrated within an
area of tissue, leading to local heating and thereby cellular
destruction. Guidance may be performed with real-time
ultrasound or MRI, the latter of which offers additional
advantages of improved resolution allowing precise treat-
ment mapping and intraprocedural thermal mapping with
MR thermometry. This is useful in treating painful bone
metastases due to destruction of periosteal innervation.64
Reports in the published literature demonstrate significant
and reproducible pain reduction.65–68
Figure 7 A 7-year-old patient with enlarging painful posterior right
shoulder mass. (A) Axial MRI with multiple fluid-fluid levels and cortical
thinning. On biopsy, this was proven to be an aneurysmal bone cyst
(ABC). (B) The patient was placed prone under general anesthesia and
bloody contents were aspirated from the ABC. Contrast injection
showed absent vessel outflow and cyst communication. Foamed
concentrated doxycycline was injected with double 18-gauge needles
to allow the sclerosant to egress to prevent lesion overfilling. (C)
Expected bony sclerosis posttreatment. MRI, magnetic resonance
imaging.
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Laser-induced thermotherapy, a modality described earlier
for treatment of OO, has also seen limited use in the treatment
of metastatic disease. Given the relatively small ablation zone
afforded by a single standard applicator, larger lesions require
multiple laser fibers for adequate treatment. Groenemeyer et
al reported using a Nd:YAG laser with a wavelength of
1,064 nm under CT guidance to treat three patients with
spinal metastases.69Delivering 4 to 10 Wof laser energy for a
total of 1,400 to 2,600 J of energy over 60 to 90 minutes
yielded a 30 to 45% pain reduction without complications.
Ahrar and Stafford recently described both preclinical studies
where they successfully ablated lumbar vertebral tumors in
four canine subjects as well as briefly outlining an open
clinical trial inwhich, at the time of publishing, seven patients
had been “successfully treated, with no adverse events.”70
Tumor types, laser parameters, and outcome measures were
not provided.
Electroporation involves delivering short, intense electrical
pulses via electrodes to a body of tissue which leads to
reversible cell membrane permeability and can ultimately
impair vital cell functions leading to cell lysis and death.71
This technique is being studied with concurrent cytotoxic
drug delivery, known as electrochemotherapy (ECT), as a
method to increase tumor cell absorption of the chemother-
apeutic agent. ECT is known to be effective in treating skin
and subcutaneous lesions,72,73 and recently studies havebeen
published demonstrating tumor response in animal models
with bone metastases.74 A single case report exists in the
literature describing curative treatment of a digital chondro-
sarcoma by two courses of ECT (yielding 90% tumor cell
necrosis), followed by marginal resection allowing the finger
to be spared.75 It is clear that more primary research is
needed before this technique can be considered among the
treatment options for osseous malignancies.
Complications of Soft Tissue and Bone
Ablation
Preprocedure consultationwith patients and familymembers
must include the risks and benefits of the ablation and related
complications, andweighed against other forms of treatment.
Conservative management that delays treatment may be an
option in certain situations, if acceptable to the patient and
family (►Fig. 9).
Precautionary measures such as correction of coagulation
factors or low platelets (< 50,000/dL) and administration of
prophylactic antibiotics will lower certain procedural risks.
Assessment of renal function is necessary if intravenous
Figure 8 Painful quadriceps desmoid tumor limiting function.
(A) A Whitaker needle (arrow) was placed into the tumor for slow
intralesional injection of 2 mL of 50% acetic acid. Real-time ultrasound
was used to observe for peritumoral extravasation. (B) Two-month
follow-up ultrasound demonstrating hollowed hypoechoic central
necrosis. The patient’s pain reduced from 9/10 to 3/10.
Figure 9 A 13-year-old boy with knee pain. (A) Radiography dem-
onstrated a vague lucent area near growth plate. (B) Coronal MRI
showing osteoid osteoma lesion and adjacent edema. (C) Due to risk of
early growth plate closure with surgical and RFA treatment, he was
treated conservatively. Follow-up plane film at the age of 16 years at
the time of closure. (D) CT-guided RFA ablation at sclerotic OO zone.
CT, computed tomography; MRI, magnetic resonance imaging; RFA,
radiofrequency ablation.
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contrast agents are given for CT or MRI. Fracture risk and
prevention must be assessed in weight-bearing bone treat-
ments (OOs andmetastatic disease), and the need for bed rest
or ambulation assist measures must be determined. Finally,
patient expectations must be addressed to better understand
the limitations ofminimally invasive pain reductionmethods,
tumor management, and the possibility of recurrence.
In seven separate bone metastasis ablation series con-
ducted for pain reduction, the reported combined complica-
tion rate was less than 3.3% (9 total complications out of 273
ablations) and possibly lower (►Table 1). Included in the bone
ablation serieswere hypervascularmetastases from renal and
thyroid tumors that potentially would have increased bleed-
ing risks. Littrup et al treated 251 oligometastatic tumors at
numerous sites with cryoablation, and reported a major (>
grade 3) complication rate of 2.3%.76 Their series included 34
bone and 76 superficial soft tissue tumors. In a study of
complete bone tumor remission by McMenomy et al, two
major events occurred in 40 procedures (5%).77 The low
complication rates are likely due to the superficial nature of
many ablation sites, the relative avascular or hypovascular
nature of many soft tissue tumors, the use of visceral and
nerve displacement methods, and tract cauterization with
RFA andmicrowave techniques. In addition,many tumor sites
have decreased or altered vascular perfusion from prior
surgical resection, chemotherapy exposure, and
radiotherapy.
Most immediate and delayed complications of bone and
soft tissue ablations are similar to those encountered with
thermal and chemical ablations performed elsewhere in the
body. Immediate complications are related to bleeding, pain
or neuritis, vessel damage, pneumothorax, and injury to
muscle, skin, or viscera from device placement and thermal
ablation effects. Delayed problems occur due to vascular
compromise, abscess or seroma formation, and adjacent
deep or superficial tissue burns. Complications are limited
by awareness of device heat specifications, extent of treat-
ment zones, and proximity of nearby structures. Intermittent
CT scanning at lower milliamperes during cryoablation will
reveal “ice ball” growth and its proximity to other structures.
Preprocedure planning and intraprocedural real-time im-
aging allow safe device placement. The literature supports
less procedural/immediate postprocedural pain resulting
from cryotherapy versus heat-based modalities, particularly
along neurovascular bundles.78 Electrosensory monitoring
Figure 10 Large soft tissue skin ulceration following thermal ablation
of a painful ischial fibrous tumor. The skin ulceration was due to
insufficient dermal temperature protection. A second small ulcer is
noted more medially. The wound eventually healed follow eschar
formation and surgical debridement.
Figure 11 A 1-month-old baby with thigh mass. (A) MRI with diffuse vastus lateralis tissue thickening. A biopsy was performed, and the diagnosis
of diffuse infantile fibromatosis was made. No therapy was undertaken, and the lesion became more discreet over time. (B) MRI at age 7
demonstrating a symptomatic enlargement of the mass. At this point, the family opted for intralesional injection treatment. (C) Ultrasound image
during 50% acetic acid injection with immediate posttreatment fluid leakage around mass. Abdominal pain and nausea 3 days later required
hospitalization for acute kidney injury from tumor lysis or acetic acid–induced crystal/cast nephropathy. Subsequent repeat biopsy showed a
fibrosarcoma with tumor dedifferentiation. MRI, magnetic resonance imaging.
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may be useful for lesions in proximity to neurovascular
structures and thermocouple placement for viscera to deter-
mine adjacent sensory innervation or temperature,
respectively.
Certain technical maneuvers before, during, and after
treatment may lessen intraoperative complications. Superfi-
cial lesion treatmentmaycause collateral injury to subdermal
and dermal layers (►Fig. 10). Fluid injection (hydrodissec-
tion) with sterile water or lidocaine in the subcutaneous soft
tissues forms an insulation buffer between the lesion and skin
or viscera to prevent injury. Placement of cooled or warmed/
tepid sterile water–soaked gauze or water-filled sterile gloves
on the overlying skin surface counteracts the damaging
effects of conducted temperatures; bladder and adjacent
bowel can be protected with warmed water instilled via a
Foley catheter. In a similar manner, sterile water infusion into
a joint space or cerebral spinal fluid may reduce collateral
heat effects on chondral surfaces, growth plates, spinal
nerves, or adjacent neurovascular structures. The injection
of carbon dioxide along nearby viscera and nerves has also
been described.79,83 Treatment to hypervascular bone and
soft tissue masses can increase bleeding risks. Posttreatment
tract cauterizationwith radiofrequency probes or microwave
antennaewill reduce this risk, similar to liver and renal tumor
ablations. Current cryoablation probes are unable to perform
tract cautery, but advances in technology may offer this
feature in the future. Pretreatment intra-arterial emboliza-
tion may also reduce bleeding but requires a second proce-
dure. Interventions in or near the chest may cause
pneumothorax and require aspiration or chest tube place-
ment. Posttreatment abscess formation may require catheter
drainage and/or antibiotics, and neuritis effect may be re-
duced with oral steroids, regional pain treatment, or physical
and/or occupational therapy. Tumor lysis (►Fig. 11) and
postembolization syndromes may require intravenous hy-
dration and hospital admission for symptom control.
Conclusion
Image-guided ablation for bone and soft tissue tumors offers
minimally invasive treatments that are safe and effective in
many situations. Appropriate patient selection and multidis-
ciplinary team consultation are keys to success. Preablation
imaging is necessary to identify anatomical landmarks, tech-
nical approaches, and optimal ablation technique. Precau-
tionary measures such as hydrodissection temperature
control can minimize potential injury to nontarget tissues.
Overall, these minimally invasive techniques represent a
burgeoning field of interventional and MSK radiology. Recent
literature demonstrates an increased utilization of current
ablative techniques used in the treatment of osseous and
soft tissue metastases and other bony lesions. New and
expanding indications may include the treatment of CB and
palliation of unresectable chordomas. Finally, novel and alter-
native complimentary technologies, including MR compatible
laser devices, versatile open intraoperative MRI systems, non-
invasive-focused ultrasound, and electroporation will allow
expanded applications of ablation treatments.
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